Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Cited by (1,078)

Items 901–1,000 of 1,078

1. Immune Checkpoint in Glioblastoma: Promising and Challenging
   Jing Huang, Fangkun Liu, Zhixiong Liu, Hui Tang, Haishan Wu, Qian-Ni Gong, Jindong Chen · 2017 · Frontiers in Pharmacology
2. Immunotherapy of melanoma
   Iwona A. Lugowska, Paweł Teterycz, Piotr Lukasz Rutkowski · 2018 · Współczesna Onkologia
3. Chemokines and cancer: new immune checkpoints for cancer therapy
   N Karin · 2018 · Current Opinion in Immunology
4. Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy
   Huijuan Song, Pengxiang Yang, Pingsheng Huang, Chuangnian Zhang, Deling Kong, Weiwei Wang · 2019 · Theranostics
5. Current and Emerging Therapies in Metastatic Pancreatic Cancer
   Manji, Gulam Abbas, Olive, Kenneth P., Saenger, Yvonne M., Oberstein, Paul · 2017 · Clinical Cancer Research
6. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer
   Hayase, Eiko, Jenq, Robert R. · 2021 · Genome Medicine
7. The role of immune checkpoint inhibition in the treatment of ovarian cancer
   Stephanie L. Gaillard, Angeles Alvarez Secord, Bradley J. Monk · 2016 · Gynecologic Oncology Research and Practice
8. The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines
   Toshifumi Doi, Takeshi Ishikawa, Tetsuya Okayama, Kaname Oka, Katsura Mizushima, Tomoyo Yasuda, Naoyuki Sakamoto, Kazuhiro Katada, Kazuhiro Kamada, Kazuhiko Uchiyama et al. · 2017 · Oncology Reports
9. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions
   Michael B. Atkins, Joseph I. Clark, David I. Quinn · 2017 · Annals of Oncology
10. Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance
    Daisuke Muraoka, Naohiro Seo, Tae Hayashi, Yoshiro Tahara, Keisuke Fujii, Isao Tawara, Yoshihiro Miyahara, Kana Okamori, Hideo Yagita∥, Seiya Imoto et al. · 2019 · Journal of Clinical Investigation
11. Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1
    Youqiong Ye, Xinwei Kuang, Zuozhong Xie, Long Liang, Zhao Zhang, Yongchang Zhang, Fangyu Ma, Qian Gao, Ruimin Chang, Heng‐Huan Lee et al. · 2020 · Genome Medicine
12. The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity
    Lili Zhang, Kerry Lynn Reynolds, Alexander Richard Lyon, Nicolas L. Palaskas, Tomas G. Neilan · 2021 · JACC CardioOncology
13. Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades
    Junyan Li, Yu‐Pei Chen, Ying‐Qin Li, Na Liu, Jun Ma · 2021 · Molecular Cancer
14. Risk of Endocrine Complications in Cancer Patients Treated with Immune Check Point Inhibitors: A Meta-Analysis
    Omar Mohammed Abdel-Rahman, Hesham M. Elhalawani, Mona Fouad · 2016 · Future Oncology
15. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment
    Qiaohong Wang, Xia Wu · 2017 · International Immunopharmacology
16. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature
    Kerry Lynn Reynolds, Amanda C. Guidon · 2018 · The Oncologist
17. The clinical promise of immunotherapy in triple-negative breast cancer
    Praveen Vikas, Nicholas C. Borcherding, Weizhou Zhang · 2018 · Cancer Management and Research
18. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages
    Thibault Vieira, Martine Antoine, Cécile Hamard, Vincent Fallet, M. Duruisseaux, Nathalie Rabbe, Anita Rodenas, Jacques L. Cadranel, Marie Wislez · 2016 · Lung Cancer
19. Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma
    Hirokazu Sadahiro, Kyung‐Don Kang, Justin Tyler Gibson, Mutsuko Minata, Hai Yu, Junfeng Shi, Rishi Raj Chhipa, Zhihong Chen, Songjian Lu, Yannick Simoni et al. · 2018 · Cancer Research
20. Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
    Carl Morrison, Sarabjot Pabla, Jeffrey M. Conroy, Mary Nesline, Sean T. Glenn, Devin C. Dressman, Antonios Papanicolau‐Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo et al. · 2018 · Journal for ImmunoTherapy of Cancer
21. Combination therapy with PD-1 or PD-L1 inhibitors for cancer
    Hidetoshi Hayashi, Kazuhiko Nakagawa · 2019 · International Journal of Clinical Oncology
22. Non-conventional Inhibitory CD4+Foxp3−PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity
    Zappasodi, Roberta, Budhu, Sadna, Hellmann, Matthew D., Postow, Michael A., Senbabaoglu, Yasin, Manne, Sasikanth, Gasmi, Billel, Liu, Cailian, Zhong, Hong, Li, Yanyun et al. · 2018 · Cancer Cell
23. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma
    Scott, Emma S, Long, Georgina V, Guminski, Alexander, Clifton-Bligh, Roderick J, Menzies, Alexander M, Tsang, Venessa H · 2018 · European Journal of Endocrinology
24. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
    Wong, Jeffrey Sum Lung, Kwok, Gerry Gin Wai, Tang, Vikki, Li, Bryan Cho Wing, Leung, Roland, Chiu, Joanne, Ma, Ka Wing, She, Wong Hoi, Tsang, Josephine, Lo, Chung Mau et al. · 2021 · Journal for ImmunoTherapy of Cancer
25. Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms
    Tiana Kordbacheh, Jamie Honeychurch, Fiona Helen Blackhall, Corinne Faivre Finn, Tim Illidge · 2017 · Annals of Oncology
26. Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
    Wouter W. van Willigen, Martine Bloemendal, Winald R. Gerritsen, Gerty Schreibelt, I. Jolanda M. de Vries, Kalijn F. Bol · 2018 · Frontiers in Immunology
27. Immune regulation of metastasis: mechanistic insights and therapeutic opportunities
    Olga S. Blomberg, Lorenzo Spagnuolo, Karin E. de Visser · 2018 · Disease Models & Mechanisms
28. Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review
    Thibaut d’Izarny-Gargas, Antoine Dürrbach, Mohamad Zaidan · 2020 · American Journal of Transplantation
29. T cell dysfunction and therapeutic intervention in cancer
    Caitlin C. Zebley, D. Zehn, Stephen Gottshalk, Hong-Bo Chi · 2024 · Nature Immunology
30. Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade
    Pai, Chien-Chun Steven, Huang, John T., Lu, Xiaoqing, Simons, Donald M., Park, Chanhyuk, Chang, Anthony, Tamaki, Whitney, Liu, Eric, Roybal, Kole T., Seagal, Jane et al. · 2019 · Immunity
31. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
    Markus Vincent Heppt, Teresa Maria Santos Amaral, Katharina Charlotte Kähler, Lucie Heinzerling, Jessica C. Hassel, Markus Meißner, Nicole Kreuzberg, Carmen Loquai, Lydia Reinhardt, Jochen Sven Utikal et al. · 2019 · Journal for ImmunoTherapy of Cancer
32. The B7:CD28 family and friends: Unraveling coinhibitory interactions
    Kelly P. Burke, Apoorvi Chaudhri, Gordon James Freeman, Arlene H. Sharpe · 2024 · Immunity
33. French Endocrine Society guidance on endocrine side effects of immunotherapy
    Castinetti, F, Albarel, F, Archambeaud, F, Bertherat, J, Bouillet, B, Buffier, P, Briet, C, Cariou, B, Caron, Ph, Chabre, O et al. · 2019 · Endocrine Related Cancer
34. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy
    Kamran A. Ahmed, Yazan Asad Abuodeh, Michelle Echevarria, J A Arrington, Dexter G. Stallworth, C. Hogue, A.O. Naghavi, S. Kim, Y. Kim, B. Patel et al. · 2016 · Annals of Oncology
35. Exhaustion of T lymphocytes in the tumor microenvironment: Significance and effective mechanisms
    Mohammad Davoodzadeh Gholami, Gholam Ali Kardar, Yousef Saeedi, Sahel Heidari, Johan Garssen, Reza Falak · 2017 · Cellular Immunology
36. Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes
    Lien Van Hoecke, Sandra Van Lint, Kenny Roose, Alexander Van Parys, Peter Vandenabeele, Johan Grooten, Jan H. Tavernier, Stefaan De Koker, Xavier Saelens · 2018 · Nature Communications
37. Current Landscape of Immunotherapy in the Treatment of Solid Tumours, with Future Opportunities and Challenges
    Nancy Alice Nixon, Normand Blais, Scott Ernst, Christian Kollmannsberger, Gwyn D. Bebb, Marcus Otho Butler, Michael Smylie, Sunil Verma · 2018 · Current Oncology
38. Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion
    Andrew J. Freeman, Stephin J. Vervoort, Kelly M. Ramsbottom, Madison J. Kelly, Jessica Michie, Lizzy Pijpers, Ricky W. Johnstone, Conor J. Kearney, Jane Oliaro · 2019 · Cell Reports
39. Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads
    Danielle M. Lussier, Elise Alspach, Jeffrey P. Ward, Alexander P. Miceli, Daniele Runci, J. Michael White, Cedric Mpoy, Cora D. Arthur, Heather N. Kohlmiller, Tyler Jacks et al. · 2021 · Proceedings of the National Academy of Sciences
40. Nutrient Competition: A New Axis of Tumor Immunosuppression
    Madhusudhanan Sukumar, Rahul Roychoudhuri, Nicholas P. Restifo · 2015 · Cell
41. Mass spectrometry-based antigen discovery for cancer immunotherapy
    Michal Bassani‐Sternberg, George Coukos · 2016 · Current Opinion in Immunology
42. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists’ perspective
    Dipti M. Karamchandani, Runjan Chetty · 2018 · Journal of Clinical Pathology
43. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review
    Maria Stelmachowska‐Banaś, Izabella Czajka-Oraniec · 2020 · Endocrine Connections
44. Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy
    Marianne Weulersse, Assia Asrir, Andrea Pichler, Lea Lemaitre, Matthias Braun, Nadège Carrié, Marie-Véronique Joubert, Marie Le Moine, Laura Do Souto, Guillaume Gaud et al. · 2020 · Immunity
45. Endocrinological side-effects of immune checkpoint inhibitors
    Francesco Torino, Salvatore Maria Corsello, Roberto Salvatori · 2016 · Current Opinion in Oncology
46. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
    Dmitriy Zamarin, Rikke Holmgaard, Jacob M. Ricca, Tamar Plitt, Peter Palese, Padmanee Sharma, Taha Merghoub, Jedd D. Wolchok, James Patrick Allison · 2017 · Nature Communications
47. Targeted drug delivery to melanoma
    Qi Liu, Manisit Das, Yun Liu, Leaf Huang · 2017 · Advanced Drug Delivery Reviews
48. Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside
    Debora Basile, Paola Di Nardo, Carla Corvaja, Silvio Ken Garattini, Giacomo Pelizzari, C. Lisanti, Lucia Bortot, Lucia Da Ros, Michele Bartoletti, Matteo Borghi et al. · 2019 · Cancers
49. Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities
    Yingyue Liu, Xiangxiang Zhou, Xin Wang · 2021 · Journal of Hematology & Oncology
50. iMLGAM: Integrated Machine Learning and Genetic Algorithm‐driven Multiomics analysis for pan‐cancer immunotherapy response prediction
    Bicheng Ye, Jun Fan, Lei Xue, Zhuang Yu, Peng Luo, Aimin Jiang, Jiaheng Xie, Qifan Li, Xiaoqing Liang, Jiaxiong Tan et al. · 2025 · iMeta
51. Considerations for treatment duration in responders to immune checkpoint inhibitors
    Marron, Thomas U, Ryan, Aideen E, Reddy, Sangeetha M, Kaczanowska, Sabina, Younis, Rania H, Thakkar, Dipti, Zhang, Jiajia, Bartkowiak, Todd, Howard, Rachel, Anderson, Kristin G et al. · 2021 · Journal for ImmunoTherapy of Cancer
52. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma
    Takushi Shirai, Tasuku Sano, Fuminao Kamijo, Nana Saito, Tomomi Miyake, Minori Kodaira, Nagaaki Katoh, Kenichi Nishie, Ryuhei Okuyama, Hisashi Uhara · 2015 · Japanese Journal of Clinical Oncology
53. Ocular and orbital side-effects of checkpoint inhibitors: a review article
    Joelle S. Antoun, Chérif Titah, Isabelle Cochereau · 2016 · Current Opinion in Oncology
54. Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
    Maarten Swart, Inge Verbrugge, Joost B. Beltman · 2016 · Frontiers in Oncology
55. Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
    Shuguang Tan, Kefang Liu, Yan Chai, Catherine W-H Zhang, Shan Gao, George F. Gao, Jianxun Qi · 2017 · Protein & Cell
56. Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer
    Timothée Chanier, Patrick Chames · 2019 · Antibodies
57. SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy
    Higham, C E, Olsson-Brown, A, Carroll, P, Cooksley, T, Larkin, J, Lorigan, P, Morganstein, D, Trainer, P J, _, _ · 2018 · Endocrine Connections
58. IL15 and T-cell Stemness in T-cell–Based Cancer Immunotherapy
    Karolina Pilipow, Alessandra Roberto, Mario Roederer, Thomas A. Waldmann, Domenico Mavilio, Enrico Lugli · 2015 · Cancer Research
59. Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses
    Leandro Machado Colli, Mitchell J. Machiela, Timothy A. Myers, Lea Jessop, Kai F. Yu, Stephen Jacob Chanock · 2016 · Cancer Research
60. Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma
    June YiJuan Hou, Caitlin D. Baptiste, Radhika Bangalore Hombalegowda, Ana Isabel Tergas, Rebecca A. Feldman, Nathaniel Jones, Sudeshna Chatterjee‐Paer, Ama Bus‐Kwolfski, Jason Dennis Wright, William M. Burke · 2016 · Cancer
61. Checkpoint inhibitors in hematological malignancies
    Chi Young Ok, Ken H. Young · 2017 · Journal of Hematology & Oncology
62. Cell death-based treatments of melanoma:conventional treatments and new therapeutic strategies
    Gianfranco Mattia, Rossella Puglisi, Barbara Ascione, Walter Malorni, Alessandra Carè, Paola Matarrese · 2018 · Cell Death and Disease
63. Reinvigorating exhausted CD8 + cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy
    Md Amir Hossain, Guilai Liu, Beiying Dai, Yaxuan Si, Qitao Yang, Junaid Wazir, Lutz Birnbaumer, Yong Yang · 2020 · Medicinal Research Reviews
64. A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)
    Sylvia Adams, Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi K Chugh, Scott M. Schuetze, Mary Dickinson Chamberlin, Barbara J. Haley, Anna Maria Storniolo, Mridula P. Reddy et al. · 2021 · Clinical Cancer Research
65. Clinical assessment of immune-related adverse events
    Aaron E. Sosa, Esther Lopez Cadena, Cristina Simon Olivé, Niki Karachaliou, Rafael Rosell · 2018 · Therapeutic Advances in Medical Oncology
66. A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer
    Cesar Augusto Santa-Maria, Taigo Kato, Jae-Hyun Park, Kazuma Kiyotani, ALFRED W. RADEMAKER, Ami N. Shah, Leeaht Gross, Luis Z. Blanco, Sarika Jain, Lisa Flaum et al. · 2018 · Oncotarget
67. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system
    Chen Chen, Bin Wu, Chenyu Zhang, Ting Xu · 2021 · International Immunopharmacology
68. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti‐ PD ‐1 antibody therapy: a report on bullous skin eruptions
    George Jour, Isabella C. Glitza, Rachel M. Ellis, Carlos Antonio Torres-Cabala, Michael T. Tetzlaff, Janet Y. Li, Priyadharsini Nagarajan, Auris Huen, Phyu P. Aung, Doina S. Ivan et al. · 2016 · Journal of Cutaneous Pathology
69. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
    Eileen F. Shiuan, Kathryn Eby Beckermann, Alpaslan Özgün, Ciara Marie Kelly, Meredith Ann McKean, Jennifer Leigh McQuade, Mary Ann Thompson, Igor J. Puzanov, John P. Greer, Suthee Rapisuwon et al. · 2017 · Journal for ImmunoTherapy of Cancer
70. The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy
    Annie Ngai Man Wong, Grant A. McArthur, Michael S. Hofman, Rodney J. Hicks · 2017 · European Journal of Nuclear Medicine and Molecular Imaging
71. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity
    Chien-Chun Steven Pai, Donald M. Simons, Xiaoqing Lu, Michael J. Evans, Junnian Wei, Yung-Hua Wang, Mingyi Chen, John Huang, Chanhyuk Park, Anthony Chang et al. · 2018 · Journal of Clinical Investigation
72. Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy
    Maria Florencia Mercogliano, Sofía Bruni, Florencia Luciana Mauro, Patricia V. Elizalde, Roxana Schillaci · 2021 · Cancers
73. Recent Advances and Challenges in Cancer Immunotherapy
    Chelsea M. Peterson, Nathan Denlinger, Yiping Yang · 2022 · Cancers
74. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma
    Georgina Venetia Long, Frank Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Pamela Salman, Erika Castillo Gutiérrez, Piotr Lukasz Rutkowski, Helen J Gogas et al. · 2023 · NEJM Evidence
75. Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
    Jing Wei, Wenke Li, Pengfei Zhang, Fukun Guo, Ming Liu · 2024 · Molecular Cancer
76. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016
    Peter E. Clark, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen Anthony Boorjian, Mark K. Buyyounouski, Jason Alexander Efstathiou, Thomas W. Flaig, Terence W. Friedlander, Richard Evan Greenberg et al. · 2016 · Journal of the National Comprehensive Cancer Network
77. Immune checkpoint blockade therapy
    Thomas Wieder, Thomas Eigentler, Ellen Brenner, Martin Röcken · 2018 · Journal of Allergy and Clinical Immunology
78. Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events
    Heinz Philipp Laubli, Catharina Balmelli, Lukas Kaufmann, Michal A. Stanczak, Mohammedyaseen Syedbasha, Dominik Vogt, Astrid Hertig, Beat P. Müller, Oliver Pascal Gautschi, Frank Stenner et al. · 2018 · Journal for ImmunoTherapy of Cancer
79. Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies
    Po‐Hong Liu, Teh‐Ia Huo, Rebecca Anne Miksad · 2018 · Seminars in Liver Disease
80. Mechanisms of Resistance to Immune Checkpoint Blockade
    David Liu, Russell William Jenkins, Ryan Joseph Sullivan · 2018 · American Journal of Clinical Dermatology
81. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation
    Praveen K. Bommareddy, Salvatore M. Aspromonte, Andrew Zloza, Samuel D. Rabkin, Howard L. Kaufman · 2018 · Science Translational Medicine
82. The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer
    Nanna Jørgensen, Gry Persson, Thomas Vauvert F. Hviid · 2019 · Frontiers in Immunology
83. Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials
    Omid Kooshkaki, Afshin Derakhshani, Negar Hosseinkhani, Mitra Torabi, Sahar Safaei, Oronzo Brunetti, Vito Racanelli, Nicola Silvestris, Behzad Baradaran · 2020 · International Journal of Molecular Sciences
84. Chemotherapy-induced cognitive impairment (CICI): An overview of etiology and pathogenesis
    Noha M. Mounier, Amany El-Shahawy Abdel-Maged, Sara A. Wahdan, Amany M. Gad, Samar S. Azab · 2020 · Life Sciences
85. Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
    Ana Maria Arance, Luis de la Cruz‐Merino, Teresa M. Petrella, Rahima Jamal, Lars Ny, Ana Carneiro, Alfonso Berrocal, Iván Márquez‐Rodas, Anna Spreafico, Victoria G. Atkinson et al. · 2022 · Journal of Clinical Oncology
86. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors
    Nicolás Gonzalo Núñez, Fiamma Berner, Ekaterina Friebel, Susanne Unger, Nina Wyss, Julia M. Martínez Gómez, Mette-Triin Purde, Rebekka Niederer, Maximilian Porsch, Christa Lichtensteiger et al. · 2023 · Med
87. Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance
    Hannah Noelle Bell, Weiping Zou · 2024 · Annual Review of Immunology
88. Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal antitumor immunity
    Choi, Yongbin, Lichterman, Jake N., Coughlin, Laura A., Poulides, Nicole, Li, Wenling, Del Valle, Priscilla, Palmer, Suzette N., Gan, Shuheng, Kim, Jiwoong, Zhan, Xiaowei et al. · 2023 · Science Immunology
89. Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges
    Francesca Tartari, Matteo Santoni, Luciano Burattini, Paola Mazzanti, Azzurra Onofri, Rossana Berardi · 2016 · Cancer Treatment Reviews
90. TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma
    Frank Stephen Hodi, Jedd D. Wolchok, Dirk Schadendorf, James Larkin, Georgina Venetia Long, Xiaozhong Qian, Abdel Saci, Tina C. Young, Sujaya Srinivasan, Han Chang et al. · 2021 · Cancer Immunology Research
91. The State of Cancer Care in America, 2016: A Report by the American Society of Clinical Oncology
    American Society of Clinical Oncology · 2016 · Journal of Oncology Practice
92. Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials
    Christopher James LaRocca, Susanne Gray Warner · 2018 · Clinical and Translational Medicine
93. MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas
    Naema Nayyar, Michael D. White, Corey M. Gill, Matthew J. Lastrapes, Mia Solana Bertalan, Alexander B. Kaplan, Megan R. D’Andrea, Ivanna V. Bihun, Andrew Kaneb, Jörg Dietrich et al. · 2019 · Blood Advances
94. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016)
    Ari Gnanasakthy, Amy M Barrett, Emily Evans, Denise D’Alessio, Carla DeMuro · 2019 · Value in Health
95. PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2
    Xiaozheng Xu, Bowen Hou, Amitkumar Fulzele, Takeya Masubuchi, Yunlong Zhao, Zijun Wu, Yanyan Hu, Yong Jiang, Yanzhe Ma, Haopeng Wang et al. · 2020 · The Journal of Cell Biology
96. PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
    Tianrui Yang, Ziren Kong, Wenbin Ma · 2020 · Human Vaccines & Immunotherapeutics
97. The therapeutic implications of immunosuppressive tumor aerobic glycolysis
    Bradley I. Reinfeld, W. Kimryn Rathmell, Tae Kon Kim, Jeffrey C. Rathmell · 2021 · Cellular and Molecular Immunology
98. Multifluid electrospinning for multi-drug delivery systems: pros and cons, challenges, and future directions
    Sahranur Tabakoglu, Dorota Kołbuk, Paweł Sajkiewicz · 2022 · Biomaterials Science
99. A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study
    David Planchard, Takashi Yokoi, Michael McCleod, Jürgen R. Fischer, Young‐Chul Kim, Marc S. Ballas, Kelvin Shi, Jean‐Charles Soria · 2016 · Clinical Lung Cancer
100. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC)
     Anna Sophie Berghoff, Gerda Ricken, Dorothee Wilhelm, Orsolya Rajky, Georg Widhalm, Karin Ute Dieckmann, Peter Birner, Rupert Bartsch, Matthias Preusser · 2016 · Journal of Neuro-Oncology